Oral Answers to Questions

Debate between Rachael Maskell and George Freeman

Tuesday 7th June 2022 Commons Chamber

[Rachael Maskell (York Central) (Lab/Co-op)]

11. What steps he is taking to support business and social business incubator and accelerator hubs.

[The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (George Freeman)]

Incubators and accelerators across the country play a vital role in helping our high-growth start-ups and scale- ups. That is why we continue to fund the strength in places fund, and are investing £100 million to pilot new innovation accelerators. That is also why, on my various tours around clusters, I recently went to the Leicester space and satellite hub, the Leeds digital health and medtech hub in the hon. Lady’s county, the Northumbria University and Ashington further education hub, and the BioYorkshire hub in her area.

[Rachael Maskell]

York’s economic future depends on releasing the talent of our entrepreneurs and social enterprises. To do that, we need to ensure that they have space to innovate and grow. In each of the last four quarters, however, we have seen the loss of 100,000 entrepreneurs, so what investment will be made to ensure that we have the infrastructure in place for the acceleration and incubation of the future business industry?

[George Freeman]

The hon. Lady makes an important point about social enterprises being mainstreamed in the business community. She may have seen the recent report by the all-party parliamentary group for social enterprise, of which I have long been a supporter, that argued that we should mainstream social enterprise in the BEIS policy framework, which is an interesting proposal. We have just announced the biggest increase in research and development and innovation funding—an increase of £25 billion over the next three years. I have asked UK Research and Innovation to focus on that incubation hub infrastructure around the country, so that we can continue to support the university and small business networks that create the opportunities for tomorrow.

UK Diagnostics Industry and Covid-19 Recovery

Debate between Rachael Maskell and George Freeman

Tuesday 10th May 2022 Commons Chamber

[George Freeman]

The hon. Gentleman makes an important point and invites me to signal again my support for what is going on in Northern Ireland. If we look at the cancer outcomes in Northern Ireland, the Queen’s University team that has been working on biomarkers and earlier detection has ended up driving not just investment, but much quicker and better outcomes for the people of Northern Ireland. The real power of the sector is that it delivers better healthcare for everybody within the values of the NHS, but also attracts investment and drives industry. I would go so far as to say that in the new landscape, companies such as Randox will develop affordable consumer diagnostic kits that can help drive earlier detection, building on to a digital interface. We can then support patients to get into trials earlier and drive research medicine. Belfast is on the frontline of that.

[Rachael Maskell (York Central) (Lab/Co-op)]

This evening’s debate has been excellent. In York, we had a company that was developing aptamers to be used in the diagnostic process. The Government did not have a grip on the governance or an understanding of what could be produced and the quality that that would bring. How is that mapping being done to ensure that every part of the manufacturing process is brought together?

[George Freeman]

The hon. Lady, not for the first time, makes an important point. As I am not a Minister in the Department of Health and Social Care, I had better defer to them on where they are on that specific mapping point. In terms of my responsibility at the Department for Business, Energy and Industrial Strategy, we are looking to grow the innovation economy by mapping the clusters of expertise around the country, including BioYorkshire, which I visited recently, and to ensure that we are aware of and supporting those clusters of research. Given that I have been invited to comment on other geographies, I will highlight how proud I am that the Norwich research park was the first place in the country to establish a local testing facility and local testing infrastructure to support it.

One thing the pandemic revealed was that, whether it is test and trace, data or epidemiological control, the best people to get on top of it are those on the ground locally. One of the lessons of the pandemic is that, yes, we need strong national leadership, but we also need to free up and trust the clinical and professional judgment on the ground.

For the record, it is important to speak about the scale of the diagnostics challenge in the pandemic. At peak, more than 700,000 PCR tests and 74,000 genomic sequences were done daily. It has been the most extraordinary turbocharging of our diagnostics infrastructure. I think everyone is aware of what we owe the diagnostics industry—that needs to be put on the record—but also that the infrastructure must be maintained for future events.

Genomic sequencing technology has been fundamental. The groundbreaking analyses of the combined SARS-CoV-2 genomic sequences and epidemiological data have supported the uploading of 2.7 million of 10.7 million genomes in GISAID—the global initiative on sharing avian influenza data. We are leaders in the global networks for genomic sequencing because of that genomics investment. More than 2 billion lateral flow tests have been provided across the UK.

I am conscious of the time. With permission, I will deal with the detailed questions that the hon. Member for Kirkcaldy and Cowdenbeath has raised in writing. I hope that I have reassured colleagues that we have absolutely learned the lesson that the diagnostics industry will never again be the poor relation. Emergencies require us to learn the lessons—we will not have got everything right, and the official inquiry is important. I would like to take the politics out of it and ensure that the clinical lessons are learned. I assure the hon. Gentleman that we are determined to ensure that the industry is put at the heart of our life sciences vision.

Question put and agreed to.

Oral Answers to Questions

Debate between Rachael Maskell and George Freeman

Tuesday 11th January 2022 Commons Chamber

[George Freeman]

I am grateful to the hon. Gentleman for raising that issue. With Queen’s University Belfast and the Randox cluster, Northern Ireland is a powerhouse in life sciences and both the Secretary of State and I have been to visit. I am delighted that the hon. Gentleman has made that point and will make sure that the Northern Ireland cluster is powerfully at the heart of our innovation strategy.

[Rachael Maskell (York Central) (Lab/Co-op)]

In York, we want to maintain momentum around the BioYorkshire project—York’s green new deal—so will the Minister set out when the project can apply for funding under the Biotechnology and Biological Sciences Research Council funding regime?

Oral Answers to Questions

Debate between Rachael Maskell and George Freeman

Tuesday 21st September 2021 Commons Chamber

[George Freeman]

I should be delighted to meet my hon. Friend soon to discuss that. Labcorp is a major global corporation whose investment in the new clinical pharmacology site is vital. It is in such companies that we need to be investing to drive private investment in research and development.

[Rachael Maskell (York Central) (Lab/Co-op)]

Time and again I have raised with the Government the opportunity to invest in BioYorkshire, which will create 4,000 jobs for my constituents, upskill 25,000 people, and deliver £5 billion in gross value added to the Government. Will the Minister meet me to discuss it? COP26 is just six weeks away, and not pursuing projects like this is holding back the improvements that we can make to our environment.

[George Freeman]

As I have said, I am wholly committed to ensuring that science innovation drives levelling up and regeneration, and I should be delighted to meet the hon. Lady. I shall be on my way to County Durham on Thursday, so perhaps I can meet her next week or the week after.